Business News

Harmony Biosciences to Acquire Zynerba Pharmaceuticals

August 15, 2023

Zygel is the first and only pharmaceutically manufactured, synthetic cannabidiol that is formulated as a patient-protected permeation-enhanced gel for transdermal delivery.

Lilly Completes Spate of Acquisitions

August 15, 2023

The completion of three acquisitions of Versanis Bio, Sigilon Therapeutics, and DICE Therapeutics boosts Eli Lilly and Company’s product pipeline in obesity, diabetes, and immunology.

Rakuten Medical Signs Exclusive Licensing Agreement with Hikma for Cancer Treatments in MENA

August 15, 2023

Under the exclusive agreement, Hikma will commercialize products in Rakuten Medical’s pipeline for cancer treatment in the Middle East and North Africa region.

United Kingdom Biotech Report Finds 29% Uptick in Funding

August 14, 2023

A report from the UK Bioindustry Association report indicated that biotech venture and public financing rose from £295 million in the first quarter to £382 million in the second quarter.

Cytomos Secures £4 Million to Develop Spectroscopy Platform

August 14, 2023

Cytomos will use the £4 million in funding to develop its dielectric spectroscopy technology.

Novartis Finalizes Chinook Therapeutics Acquisition in Deal Worth Up to $3.5 Billion

August 11, 2023

Novartis has completed its acquisition of biopharma company Chinook Therapeutics.

Regeneron Pharmaceuticals to Acquire Decibel Therapeutics

August 10, 2023

The initial collaboration between the two companies began in 2017 with an extension announced in 2021.

iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein

August 04, 2023

Under a manufacturing agreement, Northway Biotech will develop a manufacturing process for iTolerance’s fusion protein in development for regenerative therapy.

Biogen to Acquire Reata Pharmaceuticals for $7.3 Billion

August 01, 2023

Biogen’s acquisition of Reata will grant them access to Reata’s FDA-approved treatment for Friedreich’s ataxia.

AstraZeneca and Pfizer Ink $1 Billion Rare Disease Deal

August 01, 2023

AstraZeneca, via its subsidiary Alexion Pharmaceuticals, will purchase a portfolio of preclinical rare disease gene therapies from Pfizer in a deal worth up to $1 billion.